TSLPR-CART for Acute Lymphoblastic Leukemia

This trial tests a new treatment called TSLPR-CART for individuals with B-cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer. TSLPR-CART uses a person's own immune cells, modified to specifically target and kill cancer cells that overproduce a protein called TSLPR. The trial aims to determine if this treatment can benefit those whose cancer did not respond to previous treatments or recurred. It suits adults with B-ALL who have a specific gene mutation and have not succeeded with other treatments. Participants will receive their modified immune cells back after a preparation period and will be monitored to assess the treatment's effects. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this innovative therapy.

The trial requires a washout period (time without taking certain medications) of at least 2 weeks for most systemic chemotherapy and investigational agents, and 3 weeks for radiation therapy. However, there are exceptions for certain medications like intrathecal chemotherapy and some maintenance therapies, which do not require a washout period.

Research shows that TSLPR-CART, a type of CAR T-cell therapy, is undergoing safety testing in people with B-cell acute lymphoblastic leukemia (B-ALL). This marks the first human trial of this treatment. The goal is to assess the safety of TSLPR-CART for patients whose leukemia did not respond to treatment or recurred.

Previous studies on other CAR T-cell therapies have shown promising results. For instance, one study found that a similar CAR T-cell treatment improved leukemia in 83% of patients, either partially or completely, after just one treatment.

Unlike the standard chemotherapy and targeted therapies for acute lymphoblastic leukemia (ALL), TSLPR-CART is a cutting-edge treatment that involves genetically modifying a patient's own immune cells to better recognize and attack cancer cells. This therapy specifically targets the TSLPR protein on leukemia cells, which is not the focus of current treatments. Researchers are excited because TSLPR-CART has the potential to provide a more precise attack on cancer cells, potentially leading to fewer side effects and improved outcomes for patients.

Research has shown that CAR T-cell therapy effectively treats acute lymphoblastic leukemia (ALL), with over 70% of patients experiencing significant improvements. This treatment modifies a patient's immune cells to identify and destroy cancer cells. In this trial, participants will receive TSLPR-CART, which specifically targets a protein called TSLPR, often found in large amounts on some cancer cells. Studies have demonstrated that CAR T-cell therapy can greatly benefit people with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or is difficult to treat by reducing the number of cancer cells. This new approach has successfully improved outcomes for patients with blood cancers.³⁵⁶⁷⁸